JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

྾

Home
Compounds
ALA5192309

(S)-N1-((2S,5S,8S,11S,14S,17S,20S,23S,26S,29S,32S,35S)-37-amino-11-(3-amino-3-oxopropyl)-17,26-bis(4-aminobutyl)-5,29-dibenzyl-1-((S)-2-carbamoylpyrrolidin-1-yl)-14-(3-guanidinopropyl)-32-((R)-1-hydroxyethyl)-8,20-bis(hydroxymethyl)-23-isopropyl-2-methyl-1,4,7,10,13,16,19,22,25,28,31,34,37-tridecaoxo-3,6,9,12,15,18,21,24,27,30,33-undecaazaheptatriacontan-35-yl)-2-((S)-2-((S)-3-(4-hydroxyphenyl)-2-(2-mercaptonicotinamido)propanamido)-4-methylpentanamido)pentanediamide

ID: ALA5192309

Chembl Id: CHEMBL5192309

PubChem CID: 168288716

Max Phase: Preclinical

Molecular Formula: C94H140N26O24S

Molecular Weight: 2050.38

Associated Items:

Bioactivity Summary Target Summary Assay Summary

Names and Identifiers

Canonical SMILES: CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)c1cccnc1S)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(N)=O)C(C)C)[C@@H](C)O

Standard InChI: InChI=1S/C94H140N26O24S/c1-49(2)42-63(112-86(138)65(45-55-29-31-56(124)32-30-55)111-77(129)57-24-17-39-103-92(57)145)84(136)110-61(33-35-71(97)125)80(132)114-67(46-73(99)127)87(139)119-75(52(6)123)91(143)115-66(44-54-22-11-8-12-23-54)85(137)107-59(26-14-16-38-96)82(134)118-74(50(3)4)90(142)117-69(48-122)88(140)108-58(25-13-15-37-95)78(130)106-60(27-18-40-104-94(101)102)79(131)109-62(34-36-72(98)126)81(133)116-68(47-121)89(141)113-64(43-53-20-9-7-10-21-53)83(135)105-51(5)93(144)120-41-19-28-70(120)76(100)128/h7-12,17,20-24,29-32,39,49-52,58-70,74-75,121-124H,13-16,18-19,25-28,33-38,40-48,95-96H2,1-6H3,(H2,97,125)(H2,98,126)(H2,99,127)(H2,100,128)(H,103,145)(H,105,135)(H,106,130)(H,107,137)(H,108,140)(H,109,131)(H,110,136)(H,111,129)(H,112,138)(H,113,141)(H,114,132)(H,115,143)(H,116,133)(H,117,142)(H,118,134)(H,119,139)(H4,101,102,104)/t51-,52+,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,74-,75-/m0/s1

Standard InChI Key: OYTVKFVSWIZAJA-ICIPKDGVSA-N

Alternative Forms

Parent:

ALA5192309
---

Associated Targets(Human)

RAD51 Tchem DNA repair protein RAD51 homolog 1 (504 Activities)

Discover Target: RAD51

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Molecule Features

Natural Product: No	Oral: No	Chemical Probe: No	Parenteral: No
Molecule Type:	Topical: No	First In Class: No	Black Box: No
Chirality: No	Availability: No	Prodrug: No

Drug Indications

MESH ID	MESH Heading	EFO IDs	EFO Terms	Max Phase for Indication	References

Mechanisms of Action

Mechanism of Action	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	References

Calculated Properties

Molecular Weight: 2050.38	Molecular Weight (Monoisotopic): 2049.0255	AlogP: ┄	#Rotatable Bonds: ┄
Polar Surface Area: ┄	Molecular Species: ┄	HBA: ┄	HBD: ┄
#RO5 Violations: ┄	HBA (Lipinski): ┄	HBD (Lipinski): ┄	#RO5 Violations (Lipinski): ┄
CX Acidic pKa: ┄	CX Basic pKa: ┄	CX LogP: ┄	CX LogD: ┄
Aromatic Rings: ┄	Heavy Atoms: ┄	QED Weighted: ┄	Np Likeness Score: ┄

References

1. Sun G, Zhao Y, Yuan L, Lu K.. (2022) Design, synthesis and properties of peptide inhibitors based on BRCA1^856-871., 72 [PMID:35716865] [10.1016/j.bmcl.2022.128859]

Source

Source(1):

Scientific Literature